


Benita Lee

Benita Lee, MPH, is on the Research team at GoodRx. Posted on August 23, 2019

D espite outrage over the high cost of insulin, prices for popular in have continued to climb in 2019, according to a GoodRx analysis. Though prices are not climbing as quickly as they did between 2002 at the average cost of insulin therapy nearly <u>tripled</u>—the average price^{*} increased by 55% since the first quarter of 2014.

The analysis also shows that price increases this year affected a select group of insulinations insuling, those that control blood sugar throughout the day, and Afrezza, the inhaled, ul made by MannKind.

The average retail price for Afrezza has gone up by 8% since the fourth quarter of last ye prices for long-acting insulins made by Sanofi-Aventis and Novo Nordisk increased by a the same period, calling into question the pledges these manufacturers made to help re 2017, Sanofi-Aventis had <u>vowed</u> to limit annual price increases to a rate below medical in 5.4%). And Novo Nordisk promised just months before to cap annual price increases to percentages.



*average price is weighted based on the insulin units filled on a prescription claim

Good


The analysis on 23 insulins across manufacturers and insulin types—short-, intermediat acting—shows that manufacturers are still raising insulin prices, and costs now vary by depending on which insulin you take. Here, we'll walk you through how each insulin stac get the best deal on these life-saving medications.

This GoodRx analysis is based on a representative sample of U.S. prescription fills (not C comes from several sources, including pharmacies and insurers. The reported prices pe on cash prices, the so-called "usual and customary" prices or retail prices at the pharma insurance copays or co-insurance).

A note about insulin use:

One insulin unit can be defined as the amount of insulin it takes to <u>lower blood glucose</u> each individual's response is highly variable. Someone with type 2 diabetes may start w kg to 2 kg of bodyweight per day, which equates to about 40 units of insulin per day for

People with type 2 diabetes are often treated without insulin—or perhaps one type of in acting insulin—as type 2 diabetes is a disease where the body is resistant to insulin's effective 1 diabetes, an autoimmune disorder that kills pancreatic cells that make insulin, may press is needed. It's common, for example, for a person with type 1 diabetes to use both short-acting) insulin along with a basal (intermediate- or long-acting) insulin.



Why? Understandably, traditional insulins have always been cheaper than their newer of insulins offer better blood sugar control but are synthetic analogs of traditional insulins more difficult to produce.

Additionally, when patents on Humulin and Novolin expired around 2000, manufacturer Nordisk had to test new pricing strategies to remain competitive.

In 2017, for example, Novo Nordisk partnered with CVS to offer Novolin at roughly 80% le price. Both Novo Nordisk and Eli Lilly have also worked with Walmart to heavily discoun under Walmart's ReliOn line of insulin products.

Retail partnerships haven't been their only strategy. In May 2017, Eli Lilly broke from thei Humulin prices every 6 months and has since left prices alone. In fact, prices of traditio Novolin insulins, their rapid-acting analogs (**Humalog** and **Novolog**), and their Humulin 70/30, Novolog 70/30) have not gone up since then.

<u>Novolin N</u> vial (10 mL)	\$92 per vial	\$0.09 per i
<u>Humulin N</u> vial (10 mL)	\$183 per vial	\$0.18 per u
<u>Humulin N</u> KwikPen (3 mL)	\$117 per pen	\$0.39 per i
*Insulin concentrations are 100 units/mL unless otherwise stated.		

Don't miss out on savings!

Get the best ways to save on your prescriptions delivered to your inbox.


Enter your email address

Subscribe

By signing up, I agree to GoodRx's <u>terms of service</u> and privacy policy.

2) Vials are cheaper than newer dispensers

In 1985, Novo Nordisk introduced the first insulin pen, making it more convenient for painject insulin—but it came at a price. Today, retail prices of rapid-acting insulins are about for pens instead of vials. This trend isn't just relevant to rapid-acting insulins; the average the second second



New dispensers make insulin more expensive. We're seeing that again with <u>Afrezza</u> delivered as an inhalable powder. One unit of Afrezza's insulin can cost as much as 6 tin rapid-acting insulins. (Afrezza's manufacturer, MannKind, offers the medication at reduce direct purchase program.)

	Price per dispenser	Price per ii
Insulin lispro		
Generic insulin lispro vial vial (10 mL)	\$180 per vial	\$0.18 per u
Generic insulin lispro KwikPen (3 mL)	\$72 per pen	\$0.24 per u
Admelog vial (10 mL)	\$291 per vial	\$0.29 per u
<mark>Admelog</mark> SoloStar pen (3 mL)	\$187 per pen	\$0.37 per u
Humalog vial (10 mL)	\$332 per vial	\$0.33 per u
Humalog KwikPen (3 mL)	\$133 per pen	\$0.44 per u
Humalog KwikPen (3 mL, 200 units/mL)	\$264 per pen	\$0.44 per u
Humalog cartridge (3 mL)	\$132 per cartridge	\$0.44 per u
Humalog junior KwikPen (3 mL)	\$129 per pen	\$0.43 per u

Retail Prices of Rapid-Acting Insulins (Q2 2019)

Find authenticated court documents without watermarks at docketalarm.com.

Δ

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.